Compare · BIAF vs IQV
BIAF vs IQV
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and IQV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $34.42B, about 10314.0x BIAF ($3.3M).
- IQV has been more active in the news (6 items in the past 4 weeks vs 4 for BIAF).
- IQV has more recent analyst coverage (25 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- IQVIA Holdings Inc.
- Price
- -
- -
- Market cap
- $3.3M
- $34.42B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- 2013
- News (4w)
- 4
- 6
- Recent ratings
- 0
- 25
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest BIAF
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
- bioAffinity Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
- bioAffinity Technologies Announces Closing of $3.2 Million Offering
- SEC Form 424B4 filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
- bioAffinity Technologies Announces Pricing of $3.2 Million Offering
Latest IQV
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A
- SEC Form 4 filed by Director Fasano Jim
- SEC Form 4 filed by Director Danhakl John G
- IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
- IQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
- IQVIA downgraded by Morgan Stanley with a new price target
- Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain
- IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 8-K filed by IQVIA Holdings Inc.